Tadalafil Lilly (tadalafil)
- Region
- 🇪🇺 EU
- Active substance
- tadalafil
- Company
- Eli Lilly Nederland B.V.
- Status
- Authorised
- Therapeutic area
- Erectile Dysfunction
- CHMP opinion
- Thu 26 Jan 2017
- EU approval
- Wed 22 Mar 2017
- Application
- EMEA/H/C/004666
- ATC
- G04BE08
- Official record
- www.ema.europa.eu
Indication
Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required. Tadalafil Lilly is not indicated for use by women. Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Tadalafil Mylan Authorised · Mylan Pharmaceuticals Limited
- 🇪🇺 Yuvanci Authorised · Janssen-Cilag International NV
- 🇪🇺 Talmanco (previously Tadalafil Generics) Authorised · Viatris Limited
- 🇪🇺 Adcirca (previously Tadalafil Lilly) Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Cialis Authorised · Eli Lilly Nederland B.V.
Follow Tadalafil Lilly
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.